Roche TIGIT overhang could impact excitement. We remember back to the readout from Roche’s Phase II CITYSCAPE trial combining anti-PD-1 (atezolizumab) with their anti-TIGIT asset (tiragolumab) where they previewed data that was similar/as compelling as Immutep’s (median OS: 23.2 months; ORR 39%; DoR 17.6 months). This created excitement in the IO market, heralding this new anti-TIGIT as the next IO revolution. Since, with the advent of several failed Phase III trials with the tiragolumab combo (noting that Roche continue to progress the asset), the markets positivity toward new IO-IO combos may have dampened. Of course, the readthrough between Roche’s experience and Immutep’s are not at all related (different target). We simply assess the market has had recent expectations for a new IO combo dulled, and hence IMM is not experiencing the full extent of investor excitement this new OS data should warrant, in our view.
- Forums
- ASX - By Stock
- IMM
- Overnight Market report
Overnight Market report, page-1748
-
- There are more pages in this discussion • 1,116 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
33.5¢ |
Change
0.010(3.08%) |
Mkt cap ! $486.6M |
Open | High | Low | Value | Volume |
32.5¢ | 33.5¢ | 32.0¢ | $584.2K | 1.787M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 311433 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.5¢ | 113721 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 311433 | 0.330 |
3 | 89973 | 0.325 |
10 | 137686 | 0.320 |
5 | 75745 | 0.315 |
5 | 99268 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.335 | 113721 | 6 |
0.340 | 1320656 | 5 |
0.345 | 94973 | 3 |
0.350 | 509080 | 5 |
0.355 | 40082 | 2 |
Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
BM8
BATTERY AGE MINERALS LTD
Nigel Broomham, CEO
Nigel Broomham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online